FDA Opens Public Comment On Phathom's VOQUEZNA Exclusivity As Generic Filers Press Their Case
Comments are due November 23, and a second purported generic filer has surfaced in the lawsuit over the heartburn drug's exclusivity.
Phathom Pharmaceuticals, which sells the acid-blocking drug VOQUEZNA, said in an 8-K filed Monday that the FDA has opened a public docket seeking comment on questions raised by a generic-drug filer suing the agency. Comments are due November 23, 2026, and Phathom says it will defend the drug's exclusivity, which it says runs through May 3, 2032.
The docket and the challenge
The docket, No. FDA-2026-N-13038, covers legal and regulatory questions raised by BDR Pharmaceuticals, Intl. Pvt. Ltd. BDR filed a generic application referencing VOQUEZNA tablets, and the FDA rejected it. BDR then sued the agency.
The suit challenges the FDA's June 6, 2025 decision granting Phathom's Citizen Petition, which agreed that VOQUEZNA has 10 years of new chemical entity exclusivity through May 3, 2032. Phathom had first said on Friday that BDR sued in federal court in the District of Columbia; BDR alleges the FDA misapplied the GAIN Act to extend the exclusivity.
Phathom says the FDA reviewed the exclusivity through a full public process and "reached the right decision." It said it will make that case in its comments and in any appropriate court proceeding.
A second filer joins in
A second purported generic filer, Saba Ilac Sanayii Ve Ticaret AS, has filed a notice in the BDR case claiming a related pending case. It said it intends to move to consolidate its case with BDR's.
Phathom's filing lists the risks: the challengers could succeed and shorten the exclusivity, letting the FDA receive and possibly approve generic applications earlier than expected. It also warns that public comments could go against Phathom and lead the FDA to reconsider, modify or reverse its decision, and that the litigation could be lengthy and costly.
What Phathom sells
Phathom is a commercial-stage company whose three approved products, VOQUEZNA tablets and the VOQUEZNA DUAL PAK and TRIPLE PAK, contain vonoprazan, which blocks stomach acid secretion. They are approved for reflux disease and for Helicobacter pylori infection. All of its revenue comes from U.S. sales of these products, most of it from VOQUEZNA.
A Yahoo Finance report put full-year 2025 net revenue at $175.1 million, essentially all from VOQUEZNA, and said Cantor Fitzgerald sees a low likelihood the FDA will reverse its decision, keeping an Overweight rating.
Phathom has said it will file comments by the November 23 deadline and intervene in the BDR litigation.
Sources
- 8-K Filing — Phathom Pharmaceuticals, Inc. (PHAT) — SEC EDGAR
- PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity — Yahoo Finance
- Phathom Pharmaceuticals Provides Update on FDA Litigation — Yahoo Finance
- Phathom Pharmaceuticals Provides Update on Litigation Filed — globenewswire.com